Clinical Trials

    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Status: Enrolling

    ClinicalTrials.gov Number: NCT04181060

    Phone: 734.415.918

    Protocol Number: PRO00037679

    Description


    This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells.